| Symbol | VKTX |
|---|---|
| Name | VIKING THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 9920 PACIFIC HEIGHTS BOULEVARD,SUITE 350, SAN DIEGO, California, 92121, United States |
| Telephone | +1 858 704-4660 |
| Fax | — |
| — | |
| Website | https://www.vikingtherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001607678 |
| Description | Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The companys clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. Additional info from NASDAQ: |
Kelly-Gemmell Dorothy Elizabeth 🟢 acquired 47.1K shares (1 derivative) of Viking Therapeutics, Inc. (VKTX) at $31.74 ($1.3M) Transaction Date: Aug 01, 2026 | Filing ID: 000004
Read moreNew Form 3 - Viking Therapeutics, Inc. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0002144542-26-000003 <b>Size:</b> 13 KB
Read moreLian Brian 🟡 adjusted position in 73.2K shares of Viking Therapeutics, Inc. (VKTX) at $33.32 ($4.9M) Transaction Date: Jul 28, 2026 | Filing ID: 324448
Read moreZANTE GREG 🟡 adjusted position in 10.4K shares of Viking Therapeutics, Inc. (VKTX) at $33.47 Transaction Date: Jul 28, 2026 | Filing ID: 324447
Read moreMancini Marianna 🟡 adjusted position in 13.4K shares of Viking Therapeutics, Inc. (VKTX) at $33.47 Transaction Date: Jul 28, 2026 | Filing ID: 324446
Read more📋 BRIAN LIAN (Officer) plans to sell 149K shares of VIKING THERAPEUTICS, INC. (at $33.32 each, total $4.9M) Filed: Jul 29, 2026 | ID: 007394
Read moreViking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read more(30% Negative) VIKING THERAPEUTICS, INC. (VKTX) Reports Q3 2026 Financial Results
Read more📋 GREG ZANTE (Officer) plans to sell 21K shares of VIKING THERAPEUTICS, INC. (at $33.47 each, total $710K) Filed: Jul 29, 2026 | ID: 007380
Read more📋 MARIANNA MANCINI (Officer) plans to sell 18K shares of VIKING THERAPEUTICS, INC. (at $33.47 each, total $610K) Filed: Jul 29, 2026 | ID: 007376
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07104383 | VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Phase3 | Weight Loss | Active_Not_Recruiting | 2025-06-23 | 2027-08-01 | ClinicalTrials.gov |
| NCT07104500 | VK2735 for Weight Management Phase 3 | Phase3 | Weight Loss | Active_Not_Recruiting | 2025-06-23 | 2027-08-01 | ClinicalTrials.gov |
| NCT06828055 | VK2735 for Weight Management Phase 2 (Venture Oral Dosing) | Phase2 | Weight Loss | Completed | 2024-12-18 | 2025-08-15 | ClinicalTrials.gov |
| NCT06068946 | VK2735 for Weight Management Phase 2 | Phase2 | Weight Loss | Completed | 2023-08-31 | 2024-04-02 | ClinicalTrials.gov |
| NCT05203237 | Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 | Phase1 | Weight Loss | Completed | 2021-12-14 | 2024-12-03 | ClinicalTrials.gov |
| NCT04973657 | A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN | Phase1 | Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) | Completed | 2021-06-22 | 2024-11-08 | ClinicalTrials.gov |
| NCT04173065 | A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects Wi… | Phase2 | NASH - Nonalcoholic Steatohepatitis | Completed | 2019-11-15 | 2024-01-26 | ClinicalTrials.gov |
| NCT02927184 | Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia… | Phase2 | Hyperlipidemia | Completed | 2016-09-28 | 2019-03-26 | ClinicalTrials.gov |
| NCT02578095 | Acute Hip Fracture Study in Patients 65 Years or Greater | Phase2 | Hip Fractures | Completed | 2015-10-30 | 2017-12-17 | ClinicalTrials.gov |
| NCT00222508 | The Microvascular Complications Study | — | Cystic Fibrosis Related Diabetes | Completed | 2001-04-01 | 2005-07-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT02927184 |
| VK2809 | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT02927184 |
| Placebos | Other | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04173065 |
| VK2809 | Other | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04173065 |
| Placebo | Other | Phase PHASE2 | Weight Loss | COMPLETED | NCT06068946 |
| VK2735 | Other | Phase PHASE2 | Weight Loss | COMPLETED | NCT06068946 |
| VK2735 Drug | Drug | Phase PHASE1 | Weight Loss | COMPLETED | NCT05203237 |
| VK2735 Placebo | Other | Phase PHASE1 | Weight Loss | COMPLETED | NCT05203237 |
| Placebo | Other | Phase PHASE1 | Weight Loss | COMPLETED | NCT05203237 |
| VK2735 | Other | Phase PHASE1 | Weight Loss | COMPLETED | NCT05203237 |
| Placebo | Other | Phase PHASE1 | Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) | COMPLETED | NCT04973657 |
| VK0214 | Other | Phase PHASE1 | Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) | COMPLETED | NCT04973657 |
| VK2735 | Other | Phase PHASE2 | Weight Loss | COMPLETED | NCT06828055 |
| Placebo | Other | Phase PHASE2 | Weight Loss | COMPLETED | NCT06828055 |
| VK2735 | Other | Phase PHASE3 | Weight Loss | ACTIVE_NOT_RECRUITING | NCT07104500 |
| Placebo | Other | Phase PHASE2 | Hip Fractures | COMPLETED | NCT02578095 |
| VK5211 | Other | Phase PHASE2 | Hip Fractures | COMPLETED | NCT02578095 |
| VK2735 | Other | Phase PHASE3 | Weight Loss | ACTIVE_NOT_RECRUITING | NCT07104383 |
| VK2735 Drug | DRUG | Phase PHASE1 | Weight Loss | COMPLETED | NCT05203237 |
| VK2735 Placebo | DRUG | Phase PHASE1 | Weight Loss | COMPLETED | NCT05203237 |
| VK2735 | DRUG | Phase PHASE3 | Weight Loss | ACTIVE_NOT_RECRUITING | NCT07104500 |
| VK0214 | DRUG | Phase PHASE1 | Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) | COMPLETED | NCT04973657 |
| Placebos | DRUG | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04173065 |
| VK2809 | DRUG | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04173065 |
| Placebo | DRUG | Phase PHASE2 | Weight Loss | COMPLETED | NCT06828055 |
| VK5211 | DRUG | Phase PHASE2 | Hip Fractures | COMPLETED | NCT02578095 |